Bridgefront Capital’s Beta Bionics BBNX Stock Holding History

Bridgefront Capital’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,909	Closed	-$260K	–	790
2026 Q1	$260K	Buy	+25,909	New	+$383K	0.06%	428

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bridgefront Capital's BBNX Position: Q2 2026 in Review

Bridgefront Capital sold out of Beta Bionics (BBNX) in Q2 2026, closing a stake of 25,909 shares — an estimated $260K sold.

Bridgefront Capital first reported a position in BBNX in Q1 2026 and held it in 1 quarter. The position peaked at $260K in Q1 2026. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

Bridgefront Capital reported no remaining Beta Bionics position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 25,909 Beta Bionics shares in Q2 2026, an estimated $260K.
Bridgefront Capital first reported a position in Beta Bionics in Q1 2026 and held it in 1 quarter.
Bridgefront Capital's Beta Bionics position peaked at $260K in Q1 2026.
133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.